Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 137

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1A
Chunk 137
---
 our competitors; 

•our ability to effectively manage our growth; 

•the size and growth of our initial cancer target markets; 

•our ability to successfully treat additional types of cancers or at different stages; 

•actual or anticipated variations in quarterly operating results; 

•our cash position; 

•our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; 

•publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; 

•changes in the market valuations of similar companies; 

•overall performance of the equity markets; 

•sales of our common stock by us or our stockholders in the future;  

 82

•trading volume of our common stock; 

•changes in accounting practices; 

•ineffectiveness of our internal controls; 

•disputes or other developments relating to intellectual property or proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; 

•significant lawsuits, including intellectual property or stockholder litigation; 

•the impact of any natural disasters or public health emergencies; 

•general economic, political, industry and market conditions, including the rising rate of inflation, the Ukraine-Russia war and the conflict between Israel and Hamas; and 

•other events or factors, many of which are beyond our control.

The realization of any of the above risks or any of a broad range of other risks, including those described in this “Risk Factors” section, could have a dramatic and adverse impact on the market price of our common stock. 

In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In addition, broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company’s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management’s attention and resources, which would materially adversely affect our business, financial condition and results of operation. 

An active trading market for our common stock may not be sustained.

Prior to the closing of our initial public offering in September 2020, there was no public trading market for our common stock. Although our